This is a preprint.
Creating the Pick's disease International Consortium: Association study of MAPT H2 haplotype with risk of Pick's disease
- PMID: 37163045
- PMCID: PMC10168402
- DOI: 10.1101/2023.04.17.23288471
Creating the Pick's disease International Consortium: Association study of MAPT H2 haplotype with risk of Pick's disease
Update in
-
MAPT H2 haplotype and risk of Pick's disease in the Pick's disease International Consortium: a genetic association study.Lancet Neurol. 2024 May;23(5):487-499. doi: 10.1016/S1474-4422(24)00083-8. Lancet Neurol. 2024. PMID: 38631765 Free PMC article.
Abstract
Background: Pick's disease (PiD) is a rare and predominantly sporadic form of frontotemporal dementia that is classified as a primary tauopathy. PiD is pathologically defined by argyrophilic inclusion Pick bodies and ballooned neurons in the frontal and temporal brain lobes. PiD is characterised by the presence of Pick bodies which are formed from aggregated, hyperphosphorylated, 3-repeat tau proteins, encoded by the MAPT gene. The MAPT H2 haplotype has consistently been associated with a decreased disease risk of the 4-repeat tauopathies of progressive supranuclear palsy and corticobasal degeneration, however its role in susceptibility to PiD is unclear. The primary aim of this study was to evaluate the association between MAPT H2 and risk of PiD.
Methods: We established the Pick's disease International Consortium (PIC) and collected 338 (60.7% male) pathologically confirmed PiD brains from 39 sites worldwide. 1,312 neurologically healthy clinical controls were recruited from Mayo Clinic Jacksonville, FL (N=881) or Rochester, MN (N=431). For the primary analysis, subjects were directly genotyped for MAPT H1-H2 haplotype-defining variant rs8070723. In secondary analysis, we genotyped and constructed the six-variant MAPT H1 subhaplotypes (rs1467967, rs242557, rs3785883, rs2471738, rs8070723, and rs7521).
Findings: Our primary analysis found that the MAPT H2 haplotype was associated with increased risk of PiD (OR: 1.35, 95% CI: 1.12-1.64 P=0.002). In secondary analysis involving H1 subhaplotypes, a protective association with PiD was observed for the H1f haplotype (0.0% vs. 1.2%, P=0.049), with a similar trend noted for H1b (OR: 0.76, 95% CI: 0.58-1.00, P=0.051). The 4-repeat tauopathy risk haplotype MAPT H1c was not associated with PiD susceptibility (OR: 0.93, 95% CI: 0.70-1.25, P=0.65).
Interpretation: The PIC represents the first opportunity to perform relatively large-scale studies to enhance our understanding of the pathobiology of PiD. This study demonstrates that in contrast to its protective role in 4R tauopathies, the MAPT H2 haplotype is associated with an increased risk of PiD. This finding is critical in directing isoform-related therapeutics for tauopathies.
Keywords: MAPT; Pick’s disease; frontotemporal dementia; genetics; haplotype; tau.
Conflict of interest statement
M.A.N. and D.V.’s participation in this project was part of a competitive contract awarded to Data Tecnica International LLC by the National Institutes of Health to support open science research. M.A.N. also currently serves on the scientific advisory board for Character Bio Inc. and Neuron23 Inc.
Figures



References
-
- Choudhury P, Scharf EL, Paolini MA 2nd, Graff-Radford J, Alden EC, Machulda MM, et al. Pick’s disease: clinicopathologic characterization of 21 cases. Journal of neurology. 2020;267(9):2697–704. - PubMed
-
- Piguet O, Halliday GM, Reid WG, Casey B, Carman R, Huang Y, et al. Clinical phenotypes in autopsy-confirmed Pick disease. Neurology. 2011;76(3):253–9. - PubMed
Publication types
Grants and funding
- R01 DC008552/DC/NIDCD NIH HHS/United States
- R01 NS078086/NS/NINDS NIH HHS/United States
- R01 DC014942/DC/NIDCD NIH HHS/United States
- P30 AG010133/AG/NIA NIH HHS/United States
- K24 AG053435/AG/NIA NIH HHS/United States
- U19 AG063911/AG/NIA NIH HHS/United States
- P30 AG072980/AG/NIA NIH HHS/United States
- R01 NS075075/NS/NINDS NIH HHS/United States
- P01 AG066597/AG/NIA NIH HHS/United States
- MR/J009482/1/MRC_/Medical Research Council/United Kingdom
- RF1 NS120992/NS/NINDS NIH HHS/United States
- P30 AG013854/AG/NIA NIH HHS/United States
- RF1 NS112153/NS/NINDS NIH HHS/United States
- K08 AG065463/AG/NIA NIH HHS/United States
- P30 AG010124/AG/NIA NIH HHS/United States
- P50 AG023501/AG/NIA NIH HHS/United States
- U01 AG057195/AG/NIA NIH HHS/United States
- P30 AG066511/AG/NIA NIH HHS/United States
- P01 AG017586/AG/NIA NIH HHS/United States
- P30 AG062421/AG/NIA NIH HHS/United States
- R01 NS112153/NS/NINDS NIH HHS/United States
- RF1 NS118584/NS/NINDS NIH HHS/United States
- R01 AG077444/AG/NIA NIH HHS/United States
- P01 AG019724/AG/NIA NIH HHS/United States
- P30 AG066462/AG/NIA NIH HHS/United States
- R01 NS089757/NS/NINDS NIH HHS/United States
- P50 NS072187/NS/NINDS NIH HHS/United States
- P30 AG066546/AG/NIA NIH HHS/United States
- K08 AG052648/AG/NIA NIH HHS/United States
- U54 NS110435/NS/NINDS NIH HHS/United States
- MR/M023664/1/MRC_/Medical Research Council/United Kingdom
- U19 AG071754/AG/NIA NIH HHS/United States
- P30 AG072977/AG/NIA NIH HHS/United States
- P30 AG062677/AG/NIA NIH HHS/United States
- R01 AG037491/AG/NIA NIH HHS/United States
- P30 AG072958/AG/NIA NIH HHS/United States
- R01 NS109260/NS/NINDS NIH HHS/United States
- P01 AG003949/AG/NIA NIH HHS/United States
- U24 NS072026/NS/NINDS NIH HHS/United States
- WT_/Wellcome Trust/United Kingdom
- R01 AG062566/AG/NIA NIH HHS/United States
- P30 AG019610/AG/NIA NIH HHS/United States
- UG3 NS104095/NS/NINDS NIH HHS/United States
- U01 NS100620/NS/NINDS NIH HHS/United States
- MR/T046015/1/MRC_/Medical Research Council/United Kingdom
- MR/M008525/1/MRC_/Medical Research Council/United Kingdom
- U01 AG006786/AG/NIA NIH HHS/United States
- U54 NS100693/NS/NINDS NIH HHS/United States
- P30 AG072979/AG/NIA NIH HHS/United States